LCM
FHTX icon

Lynx1 Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Lynx1 Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Buy
+61,588
New +$273K 0.03% 17

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Lynx1 Capital Management's FHTX Position: Q2 2026 in Review

Lynx1 Capital Management opened a new position in Foghorn Therapeutics (FHTX) in Q2 2026: 61,588 shares worth $301K. The stake represents 0.03% of the portfolio and ranks #17 among its holdings.

103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Lynx1 Capital Management held 61,588 shares of Foghorn Therapeutics worth $301K as of Q2 2026.
  • Foghorn Therapeutics was a new Lynx1 Capital Management position in Q2 2026.
  • Foghorn Therapeutics made up 0.03% of Lynx1 Capital Management's portfolio in Q2 2026, its #17 holding.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.